First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia

Journal of Medicinal Chemistry
Hanna ChoTaebo Sim

Abstract

GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study with GNF-7 derivatives, designed to target NRAS mutant-driven AML, led to identification of the extremely potent inhibitors, 10d, 10g, and 11i, which possess single-digit nanomolar inhibitory activity against both ACK1 and GCK. These substances strongly suppress proliferation of mutant NRAS expressing AML cells via apoptosis and AKT/mTOR signaling blockade. Compound 11i is superior to GNF-7 in terms of kinase inhibitory activity, cellular activity, and differential cytotoxicity. Moreover, 10k possessing a favorable mouse pharmacokinetic profile prolonged life-span of Ba/F3-NRAS-G12D injected mice and significantly delayed tumor growth of OCI-AML3 xenograft model without causing the prominent level of toxicity found with GNF-7. Taken together, this study provides insight into the design of novel ACK1 and GCK dual inhibitors for overriding NRAS mutant-driven AML.

References

Mar 27, 2010·Chemistry & Biology·Wenjun ZhouNathanael S Gray
Apr 13, 2010·Acta Crystallographica. Section D, Biological Crystallography·P EmsleyK Cowtan
May 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christine A Pratilas, David B Solit
Jul 8, 2010·Journal of Medicinal Chemistry·Hwan Geun ChoiTaebo Sim
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Garib N MurshudovAlexei A Vagin
Oct 19, 2011·Future Medicinal Chemistry·Antonio T BainesChanning J Der
Feb 7, 2012·Journal of Cellular Physiology·Kiran Mahajan, Nupam P Mahajan
Jun 22, 2013·British Journal of Haematology·Anjali ShahPaul C Lambert
Feb 1, 2014·Nature Reviews. Drug Discovery·David A Fruman, Christian Rommel
May 21, 2014·Nature Reviews. Clinical Oncology·Yujie Zhao, Alex A Adjei
Jun 5, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Douglas B JohnsonJeffrey A Sosman
Jun 16, 2014·Nature Chemical Biology·Jochen SpiegelHerbert Waldmann
Oct 18, 2014·Nature Reviews. Drug Discovery·Adrienne D CoxChanning J Der
Dec 2, 2014·Nature Reviews. Drug Discovery·Ahmed A Samatar, Poulikos I Poulikakos
Apr 17, 2015·Nature·Heidi Ledford
Apr 23, 2016·Cell·Sai Krishna Athuluri-DivakarE Premkumar Reddy
Jun 25, 2016·The Cancer Journal·Aaron J ScottWells A Messersmith
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Aug 11, 2016·Drug Discovery Today·Candice Y Wilson, Peter Tolias
Oct 1, 2016·European Journal of Medicinal Chemistry·Vivek AsatiSanjay Kumar Bharti
Oct 18, 2016·Blood Reviews·Nikolai A PodoltsevSteven D Gore
Jan 1, 1997·Methods in Enzymology·Zbyszek Otwinowski, Wladek Minor
Apr 20, 2017·Journal of Hematology & Oncology·Caner Saygin, Hetty E Carraway
Aug 31, 2017·Journal of Translational Medicine·Seah H LimVikram M Raghunathan
Oct 7, 2017·Nature Reviews. Cancer·Zoi KarouliaPoulikos I Poulikakos
Nov 5, 2017·Seminars in Cancer Biology·Sergey G KlochkovGjumrakch Aliev
Dec 14, 2017·British Journal of Cancer·David E Durrant, Deborah K Morrison

❮ Previous
Next ❯

Citations

Jul 24, 2020·Scientific Reports·Shujuan WangYanfang Liu
May 1, 2021·International Journal of Molecular Sciences·Namkyoung KimTaebo Sim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.